The Patent Page

Chronic Kidney Disease

• Methods of preventing and treating low bone mass diseases
  
• Treatment of amyloidogenic diseases
  
• Diagnosis of diseases and conditions by analysis of histopathologically processed biological samples using liquid tissue preparations
  
• Transcriptional repression leading to Parkinson's disease
  
• Stem-cell, precursor cell, or target cell-based treatment of multi-organ failure and renal dysfunction
  
• Compositions and methods for treating sphingosine-1-phosphate (S1P) related ocular diseases and conditions
  
• Treatment of amyloidogenic diseases
  
• Pharmaceutical composition for treating or preventing degenerative and inflammatory diseases
  
• Mitochondrial inhibitors to treat human disease
  
• Methods and compositions for inhibiting diseases of the central nervous system
  
• Compositions and methods for treating sphingosine-1-phosphate (S1P) related ocular diseases and conditions
  
• Fatty acid composition for treatment of Alzheimer's disease and cognitive dysfunction
  
• Therapeutically effective 1.alpha.,25-dihydroxyvitamin D.sub.3 analogs and methods for treatment of vitamin D diseases
  
• Method of evaluating a subject for risk or predisposition of reduced renal function over time
  
• Peptide biomarkers predictive of renal function decline and kidney disease
  
• Method for diagnosing renal diseases or predispositions
  
• Methods, compositions and kits relating to chitnases and chitnase-like molecules and inflammation disease
  

Dialysis

• Safety dialysis needle/catheter system and method of use
  
• Chemokine receptor antagonists and use thereof
  
• Cartridge for electrohemodialysis
  
• Dialysis system having disposable cassette
  
• Priming system and method for dialysis systems
  
• Methods of diagnosing pancreatic inflammation by using chemokine PANEC-1 antibodies
  
• Aminopyrrolidines as chemokine receptor antagonists
  
• Methods of diagnosing pancreatic inflammation by using chemokine PANEC-1 antibodies
  

Cardiovascular

• Noninvasive method for determining the presence of systemic hypertension in a subject
  
• Methods of diagnosing atherosclerosis by measuring ApoCI
  
• Compositions comprising cardiac stem cells overexpressing specific microRNAs and methods of their use in repairing damaged myocardium
  
• Methods and compositions for targeting agents into and across the blood-brain barrier and other endothelial cell microvascular barriers
  
• Sensors for detecting substances indicative of stroke, ischemia, infection or inflammation
  
• Simulated heart valve root for training and testing
  
• Automatic detection and quantification of coronary and aortic calcium
  
• Therapeutic agents for inducing platelet fragmentation and treating thromboembolic disorders
  
• Automatic detection and quantification of plaque in the coronary arteries of subjects from CT scans
  
• Automatic segmentation of the heart and aorta in medical 3-D scans without contrast media injections
  
• Automatic detection and quantification of coronary and aortic calcium
  
• Automatic detection and quantification of coronary and aortic calcium
  
• Methods and compositions for the repair and/or regeneration of damaged myocardium using cytokines and variants thereof
  

Hypertension

• Noninvasive method for determining the presence of systemic hypertension in a subject
  
• Stable pharmaceutical composition and methods of using same
  
• Pharmaceutical composition for treating or preventing degenerative and inflammatory diseases
  
• 8-phenylisoquinolines and pharmaceutical composition used in treatment for sepsis
  
• Pharmaceutical compositions for the treatment of virus infection
  
• Stable pharmaceutical composition and methods of using same
  
• User interface with 3D environment for configuring stimulation therapy
  
• Phosphate-binding protein, pharmaceutical compositions containing same and use thereof
  
• GLP-1 analogues and their pharmaceutical salts and uses
  
• Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
  
• Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same
  
• Cycloalkyl containing thienopyrimidines for pharmaceutical compositions
  
• Phosphate-binding protein, pharmaceutical compositions containing same and use thereof
  
• Methods for treating conditions such as dystonia and post-stroke spasticity with clonidine
  
• Method of spray freeze drying proteins for pharmaceutical administration
  
• Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same
  
• Systems, devices, and methods including catheters having acoustically actuatable waveguide components for delivering a sterilizing stimulus to a region proximate a surface of the catheter
  
• Methods for treating conditions such as dystonia and post-stroke spasticity with clonidine
  

Diabetes

• Electronic skin patch for real time monitoring of cardiac activity and personal health management
  
• Methods of isolating non-senescent cardiac stem cells and uses thereof
  
• Automatic detection and quantification of plaque in the coronary arteries of subjects from CT scans
  
• Vestibular stimulation apparatus and associated methods of use
  
• Method and device for diagnosing and treating insulin-like growth factor deficiency disorders
  
• Dialysis system having disposable cassette
  
• Method and composition for preventing or reducing the symptoms of insulin resistance syndrome
  
• Insulin-like growth factor agonist molecules
  
• Methods of diagnosing pancreatic inflammation by using chemokine PANEC-1 antibodies
  
• Methods of diagnosing pancreatic inflammation by using chemokine PANEC-1 antibodies
  
• Oxadiazole beta carboline derivatives as antidiabetic compounds
  

Inflammation

• Interleukin-13 binding proteins
  
• Inhibition of inflammation using antagonists of MUC1
  
• Pharmaceutical composition for treating or preventing degenerative and inflammatory diseases
  
• Methods and compositons featuring TGF-beta antagonists for the treatment of marfan syndrome and associated disorders
  
• Prolyl endopeptidase inhibitors for reducing or preventing neutrophilic inflammation
  
• Drug depots having different release profiles for reducing, preventing or treating pain and inflammation
  
• Antibodies that bind TGF-alpha and epiregulin
  
• Benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses
  
• Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
  
• Fusion protein capable of binding VEGF-A and TNF-alpha
  
• Methods of diagnosing pancreatic inflammation by using chemokine PANEC-1 antibodies
  
• Methods and compositons featuring TGF-beta antagonists for the treatment of marfan syndrome and associated disorders
  
• Methods, compositions and kits relating to chitnases and chitnase-like molecules and inflammation disease
  
• Minimally-invasive measurement of esophageal inflammation
  
• Methods and compositions for the repair and/or regeneration of damaged myocardium using cytokines and variants thereof
  
• Methods of diagnosing pancreatic inflammation by using chemokine PANEC-1 antibodies
  

Vascular Disease

• Methods and compositions for targeting agents into and across the blood-brain barrier and other endothelial cell microvascular barriers
  
• Central venous pressure sensor and method to control a fluid or volume overload therapy
  
• Methods of diagnosing atherosclerosis by measuring ApoCI
  
• Central venous pressure sensor and method to control a fluid or volume overload therapy
  
• Methods and compositions for targeting agents into and across the blood-brain barrier and other endothelial cell microvascular barriers
  
• Compositions and methods for the prevention and treatment of cardiovascular diseases
  
• Crystal structure of the pro form of a matrix metalloproteinase and an allosteric processing inhibitor
  
• Crystal structure of the pro form of a matrix metalloproteinase and an allosteric processing inhibitor
  
• Woven vascular treatment devices
  

Vascular Calcification

• Automatic detection and quantification of coronary and aortic calcium
  
• Fetuin-MGP-mineral complex in serum assayed to determine calcification risk
  
• Automatic detection and quantification of plaque in the coronary arteries of subjects from CT scans
  
• Automatic segmentation of the heart and aorta in medical 3-D scans without contrast media injections
  
• Automatic detection and quantification of coronary and aortic calcium
  
• Automatic detection and quantification of coronary and aortic calcium
  
• Automated calcium scoring of the aorta
  

Medicine

• Growth arrest homebox gene
  
• Growth arrest homeobox gene
  
• Diagnostic assay for human matrix Gla-protein and its use as a biomarker
  
• Osf2/Cbfa1 nucleic acids and methods of use therefor
  
• Branched PEG remodeling and glycosylation of glucagon-like peptide-1 [GLP-1]
  
• Diagnostic assay for human matrix Gla-protein and its use as a biomarker
  
• Growth arrest homebox gene
  
• Growth arrest homeobox gene
  
• Osf2/Cbfa1 nucleic acids and methods of use therefor
  
• Growth arrest homebox gene
  
• Growth arrest homeobox gene
  
• Growth arrest homebox gene
  
• Once-a-week administration of 25-hydroxy vitamin D.sub.3 to sustain elevated steady-state pharmacokinetic blood concentration
  
• Method for diagnosing renal diseases or predispositions
  
• Isolation of membrane vesicles from biological fluids and methods of using same
  
• Bacterial virulence factors and uses thereof
  
• Biofilm-removing antimicrobial compositions and uses thereof
  
• Certain heterocycles, compositions thereof, and methods for their use
  
• Electrical stimulation of the sympathetic nerve chain
  
• Optimized gas supply using photoplethysmography
  
• Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same
  
• Pyrazolylbenzothiazole derivatives and their use as therapeutic agents
  
• Piperidinyl-substituted lactams as GPR119 modulators
  
• Pirfenidone therapy and inducers of cytochrome P450
  
• Fused heterocyclic compounds as ion channel modulators
  
• Pyrido[2,3-b]pyrazine compounds useful as IP receptor agonist
  
• Cycloalkyl containing thienopyrimidines for pharmaceutical compositions
  
• Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
  
• Neuroprotection by hepatic cells and hepatocyte secretory factors
  
• Therapeutic agents for inducing platelet fragmentation and treating thromboembolic disorders
  
• Phosphate-binding protein, pharmaceutical compositions containing same and use thereof
  
• Fusion protein capable of binding VEGF-A and TNF-alpha
  
• Growth arrest homebox gene
  
• Growth arrest homebox gene
  
• Growth arrest homeobox gene
  
• Automatic detection and quantification of coronary and aortic calcium
  
• Growth arrest homebox gene
  
• Methods for treating conditions such as dystonia and post-stroke spasticity with clonidine
  
• Vestibular stimulation apparatus and associated methods of use
  
• Activatable probes and methods for in vivo gene detection
  
• Method and composition for preventing or reducing the symptoms of insulin resistance syndrome
  
• Insulin-like growth factor agonist molecules
  
• IGF-I point variants
  
• Method of spray freeze drying proteins for pharmaceutical administration
  
• Automated calcium scoring of the aorta
  
• Growth arrest homebox gene
  
• Growth arrest homeobox gene
  
• Personalized health records with associative relationships
  
• Devices and methods for electrode implantation
  
• Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT.sub.2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
  
• Highly selective 5-HT(2C) receptor agonists that show anti-psychotic effects with antagonist activity at the 5-HT(2B) receptor
  
• Alkylamido compounds and uses thereof
  
• Atropisomer of pyrrole derivative
  
• Fused heterocyclic compounds as ion channel modulators
  
• Heterocyclic compounds and their uses
  
• Testosterone gel and method of use
  
• Defensin-antigen fusion proteins
  
• Open-reading-frame (ORF) phage display
  
• Crystal structure of the pro form of a matrix metalloproteinase and an allosteric processing inhibitor
  
• Biofilm-removing antimicrobial compositions and uses thereof
  
• Crystallized oxalate decarboxylase and methods of use
  
• Composition and method for reducing blood glucose levels
  
• Antibodies for epidermal growth factor receptor 3 (HER3)
  
• Dual variable domain immunoglobulins and uses thereof
  
• Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same
  
• Therapeutic compositions
  
• Solubilisation of membrane proteins
  
• Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
  
• Open-reading-frame (ORF) phage display
  
• Crystal structure of the pro form of a matrix metalloproteinase and an allosteric processing inhibitor
  
• Methods of detecting factor D with anti-factor D antibodies
  
• Method for the carry-over protection in DNA amplification systems targeting methylation analysis achieved by a modified pre-treatment of nucleic acids
  
• Methods and compositions for the disruption of biofilms
  
• IPV-DPT vaccine
  
• Antibodies to modified human IGF-1/E peptides
  
• Systems, devices, and methods including catheters having acoustically actuatable waveguide components for delivering a sterilizing stimulus to a region proximate a surface of the catheter
  
• Methods for treating conditions such as dystonia and post-stroke spasticity with clonidine
  
• Quinolines and related analogs as sirtuin modulators
  
• Methods, compositions and kits relating to chitnases and chitnase-like molecules and inflammation disease
  
• Halogenated phenols for diagnostics, antioxidant protection and drug delivery
  
• Modulation of innate immunity receptors' signaling by microRNAs miR-146a and miR-146b
  
• Soluble hybrid Fc.gamma. receptors and related methods
  
• Minimally-invasive measurement of esophageal inflammation
  
• Methods and compositions for the repair and/or regeneration of damaged myocardium using cytokines and variants thereof
  
• Systems and methods for providing a real-time health risk assessment
  
• Electrical stimulation of the sympathetic nerve chain
  
• Piperidinyl-substituted lactams as GPR119 modulators
  
• Pirfenidone therapy and inducers of cytochrome P450
  
• Fused heterocyclic compounds as ion channel modulators
  
• Oxadiazole beta carboline derivatives as antidiabetic compounds
  
• Process to prepare treprostinil
  
• Inhibitors of cathepsin S for prevention or treatment of obesity-associated disorders
  
• Osmotic drug delivery system
  
• Intraluminal medical devices in combination with therapeutic agents
  
• Woven vascular treatment devices
  
• Method for selecting a clinical treatment plan tailored to patient defined health goals
  
• Method for non-contrast enhanced magnetic resonance angiography
  
• Activatable probes and methods for in vivo gene detection
  
• IGF-I variants
  
• Growth arrest homebox gene